<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cholesterin-/Steroid-Biosynthese - Teil 2</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #8b5cf6;
            --secondary-color: #ec4899;
            --accent-color: #06b6d4;
            --success-color: #10b981;
            --warning-color: #f59e0b;
            --danger-color: #ef4444;
            --info-color: #3b82f6;
            --text-primary: #1f2937;
            --text-secondary: #4b5563;
            --text-muted: #6b7280;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--primary-color), var(--accent-color));
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e2e8f0;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--primary-color), var(--accent-color));
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        .pathway-diagram h5 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }
        
        .pathway-diagram p {
            color: var(--text-secondary);
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fef3c7, #fde68a);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '⚠️';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fbbf24);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #ecfdf5, #d1fae5);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #065f46;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #065f46;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--accent-color), #0ea5e9);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--success-color), var(--accent-color));
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Special steroid pathway styling */
        .steroid-pathway {
            background: linear-gradient(135deg, #fdf4ff, #fae8ff);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .desmosterol-pathway {
            background: linear-gradient(135deg, #f0f9ff, #e0f2fe);
            border: 2px solid var(--accent-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        /* Hormone boxes for CAH */
        .hormone-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--secondary-color), #be185d);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .hormone-box.elevated {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        .hormone-box.decreased {
            background: linear-gradient(135deg, #6b7280, #4b5563);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .header p {
                font-size: 1.1rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
            
            .subsection {
                padding: var(--spacing-md);
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>🧬 Cholesterin-/Steroid-Biosynthese</h1>
            <p>Teil 2: Desmosterolosis & Kongenitale Nebennierenhyperplasie</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>📚 Lerneinheit Teil 2</h3>
            <p>Dieser zweite Teil behandelt Desmosterolosis, die verschiedenen Formen der kongenitalen Nebennierenhyperplasie und erweiterte Steroidogenese-Störungen.</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('desmosterolosis')">1. Desmosterolosis</button>
            <button class="nav-btn" onclick="showSection('cah21')">2. 21-Hydroxylase CAH</button>
            <button class="nav-btn" onclick="showSection('cah-andere')">3. Andere CAH-Formen</button>
            <button class="nav-btn" onclick="showSection('steroidogenese')">4. Erweiterte Störungen</button>
        </div>

        <!-- Desmosterolosis -->
        <div class="content-section active" id="desmosterolosis">
            <h2 class="section-title">💎 Desmosterolosis</h2>

            <div class="subsection">
                <h3>Definition und Epidemiologie</h3>
                <div class="case-study">
                    <h4>🔬 Krankheitsdefinition</h4>
                    <p><strong>Desmosterolosis</strong> ist eine ultra-seltene autosomal-rezessive Störung der terminalen Cholesterin-Biosynthese durch Defekt der Desmosterol-Reduktase (DHCR24).</p>
                    
                    <p><strong>Epidemiologie:</strong></p>
                    <ul>
                        <li><strong>Prävalenz:</strong> < 30 bekannte Fälle weltweit</li>
                        <li><strong>Inzidenz:</strong> Geschätzt <1:1.000.000</li>
                        <li><strong>Geografische Verteilung:</strong> Sporadisch, keine ethnischen Häufungen</li>
                        <li><strong>Geschlechtsverteilung:</strong> M:F = 1:1</li>
                        <li><strong>Erstbeschreibung:</strong> 2007 (Waterham et al.)</li>
                    </ul>
                </div>

                <div class="desmosterol-pathway">
                    <h4>DHCR24-Enzym und Metabolismus</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #f8fafc; padding: 15px; border-radius: 8px; text-align: center; width: 100%;">
                            <h5 style="color: #0891b2; margin-bottom: 10px;">Kandel-Russell Pathway (85% der Cholesterin-Synthese)</h5>
                        </div>
                        
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box">24,25-Dihydrolanosterol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">↓</span>
                            <div class="metabolite-box">Desmosterol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">↓</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">DHCR24 (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">24-Dehydrocholesterin Reduktase</div>
                            <div style="text-align: center; color: #ef4444; font-size: 0.9em;">NADPH + H⁺ abhängig</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">↓</span>
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #10b981, #059669); font-size: 1.1em; padding: 15px 25px;">Cholesterin ↓</div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Parameter</th>
                            <th>Gen</th>
                            <th>Protein</th>
                            <th>Lokalisation</th>
                            <th>Funktion</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>DHCR24</strong></td>
                            <td>DHCR24 (1p33)</td>
                            <td>24-Dehydrocholesterin Reduktase</td>
                            <td>ER-Membran</td>
                            <td>Δ24-Reduktion von Desmosterol</td>
                        </tr>
                        <tr>
                            <td><strong>Alternative Namen</strong></td>
                            <td>SELADIN-1</td>
                            <td>Selective Alzheimer Disease Indicator-1</td>
                            <td>Ubiquitär exprimiert</td>
                            <td>Neuroprotektive Wirkung?</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Molekulare Pathophysiologie</h3>
                <div class="pathway-diagram">
                    <h4>Desmosterol-Akkumulation und Folgen</h4>
                    
                    <div style="background: linear-gradient(135deg, #fef2f2, #fee2e2); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #fca5a5;">
                        <div style="text-align: center; margin-bottom: 20px;">
                            <h5 style="color: #dc2626; margin-bottom: 15px;">Pathophysiologische Mechanismen</h5>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                            <div>
                                <p style="color: #dc2626; font-weight: 600; margin-bottom: 10px;">1. Cholesterin-Mangel:</p>
                                <ul style="font-size: 0.9em; color: #dc2626;">
                                    <li>Membranfluidität ↑ (milde Form)</li>
                                    <li>Weniger dramatisch als bei SLOS</li>
                                    <li>Partielle Kompensation möglich</li>
                                    <li>Steroidogenese beeinträchtigt</li>
                                </ul>
                            </div>
                            <div>
                                <p style="color: #dc2626; font-weight: 600; margin-bottom: 10px;">2. Desmosterol-Akkumulation:</p>
                                <ul style="font-size: 0.9em; color: #dc2626;">
                                    <li>Weniger toxisch als 7-DHC</li>
                                    <li>Membranintegration möglich</li>
                                    <li>Partielle Cholesterin-Funktion</li>
                                    <li>Mildere Phänotypen</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="highlight-box">
                    <h4>Besonderheiten gegenüber SLOS</h4>
                    <p><strong>Wichtige Unterschiede:</strong></p>
                    <ul>
                        <li><strong>Desmosterol vs. 7-DHC:</strong> Weniger toxisch, teilweise funktional</li>
                        <li><strong>Kandel-Russell vs. Bloch:</strong> Beeinträchtigt 85% vs. 15% der Cholesterin-Synthese</li>
                        <li><strong>Entwicklungsdefekte:</strong> Weniger schwer, spätere Manifestation</li>
                        <li><strong>Neurodegeneration:</strong> Progressiv, postnatale Verschlechterung</li>
                        <li><strong>Lebenserwartung:</strong> Länger als schwere SLOS-Formen</li>
                    </ul>
                    
                    <p><strong>DHCR24/SELADIN-1 Funktionen:</strong></p>
                    <ul>
                        <li><strong>Cholesterin-Biosynthese:</strong> Rate-limiting für Kandel-Russell Pathway</li>
                        <li><strong>Neuroprotektion:</strong> Anti-apoptotische Wirkung</li>
                        <li><strong>Alzheimer-Assoziation:</strong> Vermindert bei Alzheimer-Patienten</li>
                        <li><strong>Zellzyklusregulation:</strong> G1/S-Transition</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Klinisches Spektrum</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>System</th>
                            <th>Häufigkeit</th>
                            <th>Merkmale</th>
                            <th>Verlauf</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>ZNS</strong></td>
                            <td>100%</td>
                            <td>Mikrozephalie, ID, Krampfanfälle, Ataxie</td>
                            <td>Progressiv</td>
                        </tr>
                        <tr>
                            <td><strong>Wachstum</strong></td>
                            <td>90%</td>
                            <td>Intrauterine/postnatale Wachstumsretardierung</td>
                            <td>Persistierend</td>
                        </tr>
                        <tr>
                            <td><strong>Fazial</strong></td>
                            <td>80%</td>
                            <td>Subtile Dysmorphie, breite Nasenwurzel</td>
                            <td>Nicht-progressiv</td>
                        </tr>
                        <tr>
                            <td><strong>Extremitäten</strong></td>
                            <td>50%</td>
                            <td>Brachydaktylie, Klinodaktylie</td>
                            <td>Statisch</td>
                        </tr>
                        <tr>
                            <td><strong>Ophthalmologisch</strong></td>
                            <td>60%</td>
                            <td>Katarakt, Strabismus</td>
                            <td>Kann progressiv sein</td>
                        </tr>
                        <tr>
                            <td><strong>Kardiovaskulär</strong></td>
                            <td>30%</td>
                            <td>Angeborene Herzfehler (meist mild)</td>
                            <td>Statisch</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>📊 Phänotypische Variabilität</h4>
                    <p><strong>Schwere Form (seltener):</strong></p>
                    <ul>
                        <li>Frühe Manifestation (neonatal)</li>
                        <li>Schwere Mikrozephalie, Krampfanfälle</li>
                        <li>Multiple Fehlbildungen</li>
                        <li>Reduzierte Lebenserwartung</li>
                    </ul>
                    
                    <p><strong>Milde Form (häufiger):</strong></p>
                    <ul>
                        <li>Spätere Manifestation (Säuglingsalter)</li>
                        <li>Entwicklungsverzögerung, milde ID</li>
                        <li>Subtile Dysmorphie</li>
                        <li>Längeres Überleben möglich</li>
                    </ul>
                    
                    <p><strong>Besondere Merkmale:</strong></p>
                    <ul>
                        <li><strong>Keine Polydaktylie:</strong> Im Gegensatz zu SLOS</li>
                        <li><strong>Keine Genitalanomalien:</strong> Normale Geschlechtsentwicklung</li>
                        <li><strong>Progressiver Verlauf:</strong> Postnatale Verschlechterung</li>
                        <li><strong>Katarakt häufig:</strong> Bei 60% der Patienten</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Diagnostik und Molekulargenetik</h3>
                <div class="pathway-diagram">
                    <h4>Biochemische Diagnostik</h4>
                    
                    <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #3b82f6;">
                        <p><strong>Sterol-Profil Analyse:</strong></p>
                        <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 15px; margin: 15px 0;">
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #ef4444, #dc2626); margin: 0 0 10px 0; width: 100%;">Desmosterol ↑↑</div>
                                <p style="font-size: 0.9em;">Normal: <0.5 mg/dl<br>Desmosterolosis: 5-20 mg/dl</p>
                            </div>
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #059669, #047857); margin: 0 0 10px 0; width: 100%;">Cholesterin ↓</div>
                                <p style="font-size: 0.9em;">Meist moderat reduziert<br>50-120 mg/dl</p>
                            </div>
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #0891b2, #0e7490); margin: 0 0 10px 0; width: 100%;">7-DHC normal</div>
                                <p style="font-size: 0.9em;">Wichtige DD zu SLOS<br><0.5 mg/dl</p>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Mutation</th>
                            <th>Typ</th>
                            <th>Häufigkeit</th>
                            <th>Enzymaktivität</th>
                            <th>Phänotyp</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>c.1054C>T (p.Arg352Trp)</strong></td>
                            <td>Missense</td>
                            <td>20%</td>
                            <td>5-10%</td>
                            <td>Moderat</td>
                        </tr>
                        <tr>
                            <td><strong>c.748G>T (p.Glu250X)</strong></td>
                            <td>Nonsense</td>
                            <td>15%</td>
                            <td>0%</td>
                            <td>Schwer</td>
                        </tr>
                        <tr>
                            <td><strong>c.425A>G (p.Tyr142Cys)</strong></td>
                            <td>Missense</td>
                            <td>10%</td>
                            <td>2-5%</td>
                            <td>Schwer</td>
                        </tr>
                        <tr>
                            <td><strong>Large deletions</strong></td>
                            <td>CNV</td>
                            <td>25%</td>
                            <td>0%</td>
                            <td>Variabel</td>
                        </tr>
                    </tbody>
                </table>

                <div class="highlight-box">
                    <h4>Therapeutische Ansätze</h4>
                    <p><strong>Cholesterin-Supplementation:</strong></p>
                    <ul>
                        <li><strong>Dosierung:</strong> 50-100 mg/kg/d oral</li>
                        <li><strong>Wirksamkeit:</strong> Begrenzt, da Desmosterol teilweise funktional</li>
                        <li><strong>Monitoring:</strong> Sterol-Profil alle 6 Monate</li>
                    </ul>
                    
                    <p><strong>Symptomatische Therapie:</strong></p>
                    <ul>
                        <li><strong>Antiepileptika:</strong> Bei Krampfanfällen</li>
                        <li><strong>Physiotherapie:</strong> Bei Ataxie/Spastik</li>
                        <li><strong>Ophthalmologie:</strong> Kataraktchirurgie</li>
                        <li><strong>Entwicklungsförderung:</strong> Multidisziplinär</li>
                    </ul>
                    
                    <p><strong>Experimentelle Ansätze:</strong></p>
                    <ul>
                        <li><strong>DHCR24 Enhancer:</strong> Pharmakologische Verstärkung</li>
                        <li><strong>Alternative Pathways:</strong> Bloch-Pathway Aktivierung</li>
                        <li><strong>Antioxidantien:</strong> Vitamin E, CoQ10</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah21')">Weiter zur 21-Hydroxylase CAH →</button>
            </div>
        </div>

        <!-- 21-Hydroxylase CAH -->
        <div class="content-section" id="cah21">
            <h2 class="section-title">🔥 21-Hydroxylase Mangel (CAH)</h2>

            <div class="subsection">
                <h3>Definition und Epidemiologie</h3>
                <div class="case-study">
                    <h4>🔬 Kongenitale Nebennierenhyperplasie (CAH)</h4>
                    <p><strong>21-Hydroxylase-Mangel</strong> ist die häufigste Form der kongenitalen Nebennierenhyperplasie, verursacht durch Defekte im CYP21A2-Gen.</p>
                    
                    <p><strong>Epidemiologie:</strong></p>
                    <ul>
                        <li><strong>Gesamtinzidenz:</strong> 1:10.000 - 1:15.000 Geburten</li>
                        <li><strong>Klassische Form:</strong> 1:15.000 (75% Salzverlust, 25% einfach virilisierend)</li>
                        <li><strong>Nicht-klassische Form:</strong> 1:1.000 (sehr häufig!)</li>
                        <li><strong>Ethnische Variationen:</strong> Höher bei Aschkenasi-Juden (1:27 Träger)</li>
                        <li><strong>Geschlechtsverteilung:</strong> M:F = 1:1 (autosomal-rezessiv)</li>
                    </ul>
                </div>

                <div class="steroid-pathway">
                    <h4>Steroidogenese und 21-Hydroxylase</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); font-size: 1.1em; padding: 15px 25px;">Cholesterin</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">↓</span>
                        
                        <div class="enzyme-box">CYP11A1 (Side-chain cleavage)</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">↓</span>
                        
                        <div class="metabolite-box" style="background: linear-gradient(135deg, #ec4899, #be185d);">Pregnenolon</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">↓</span>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; width: 100%;">
                            <div style="text-align: center;">
                                <h5 style="color: #3b82f6; margin-bottom: 15px;">Kortisol-Synthese</h5>
                                <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                    <div class="metabolite-box">17-OH-Pregnenolon</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="metabolite-box">17-OH-Progesteron</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="enzyme-box defect">CYP21A2 (DEFEKT)</div>
                                    <div style="font-weight: 600; color: #ef4444; font-size: 0.9em;">21-Hydroxylase</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="hormone-box decreased">11-Deoxykortisol ↓</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="hormone-box decreased">Kortisol ↓↓</div>
                                </div>
                            </div>
                            
                            <div style="text-align: center;">
                                <h5 style="color: #f59e0b; margin-bottom: 15px;">Mineralokortikoid-Synthese</h5>
                                <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                    <div class="metabolite-box">Progesteron</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="enzyme-box defect">CYP21A2 (DEFEKT)</div>
                                    <div style="font-weight: 600; color: #ef4444; font-size: 0.9em;">21-Hydroxylase</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="hormone-box decreased">11-Deoxykortikosteron ↓</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">↓</span>
                                    <div class="hormone-box decreased">Aldosteron ↓↓</div>
                                </div>
                            </div>
                        </div>
                        
                        <div style="margin-top: 20px; text-align: center;">
                            <h5 style="color: #ef4444; margin-bottom: 10px;">🔄 Kompensatorische Androgen-Produktion</h5>
                            <div class="hormone-box elevated">17-OH-Progesteron ↑↑↑</div>
                            <span class="arrow">→</span>
                            <div class="hormone-box elevated">Androstendion ↑↑</div>
                            <span class="arrow">→</span>
                            <div class="hormone-box elevated">Testosteron ↑↑</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Klinische Formen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Form</th>
                            <th>Enzymaktivität</th>
                            <th>17-OHP (ng/ml)</th>
                            <th>Klinische Merkmale</th>
                            <th>Manifestationsalter</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Salzverlust (SW)</strong></td>
                            <td>0-1%</td>
                            <td>>20.000</td>
                            <td>Virilisierung + Salzverlust</td>
                            <td>Neonatal (1-3 Wochen)</td>
                        </tr>
                        <tr>
                            <td><strong>Einfach virilisierend (SV)</strong></td>
                            <td>1-5%</td>
                            <td>3.000-20.000</td>
                            <td>Virilisierung ohne Salzverlust</td>
                            <td>Neonatal/frühe Kindheit</td>
                        </tr>
                        <tr>
                            <td><strong>Nicht-klassisch (NC)</strong></td>
                            <td>5-50%</td>
                            <td>300-3.000</td>
                            <td>Milde Hyperandrogenämie</td>
                            <td>Pubertät/Erwachsenenalter</td>
                        </tr>
                        <tr>
                            <td><strong>Asymptomatisch</strong></td>
                            <td>>50%</td>
                            <td><300</td>
                            <td>Keine klinischen Symptome</td>
                            <td>Nie</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>👶 Neonatale Präsentation</h4>
                    <p><strong>Weibliche Neugeborene (klassische CAH):</strong></p>
                    <ul>
                        <li><strong>Ambige Genitalien:</strong> Virilisierung durch pränatale Androgen-Exposition</li>
                        <li><strong>Prader-Skala:</strong> Grad II-V (Klitorishypertrophie bis komplett männliches Erscheinungsbild)</li>
                        <li><strong>Interne Strukturen:</strong> Normal weiblich (Uterus, Ovarien)</li>
                        <li><strong>Diagnose:</strong> Meist bei Geburt durch Genitaluntersuchung</li>
                    </ul>
                    
                    <p><strong>Männliche Neugeborene:</strong></p>
                    <ul>
                        <li><strong>Genitalien:</strong> Normal oder leichte Hyperpigmentierung</li>
                        <li><strong>Salzverlustkrise:</strong> Oft erste Manifestation (Woche 1-3)</li>
                        <li><strong>Diagnose:</strong> Oft verzögert, erst bei Salzverlustkrise</li>
                        <li><strong>Mortalität:</strong> Höher durch späte Diagnose</li>
                    </ul>
                    
                    <p><strong>Salzverlustkrise (75% der klassischen Fälle):</strong></p>
                    <ul>
                        <li><strong>Zeitpunkt:</strong> Meist Tag 5-15 des Lebens</li>
                        <li><strong>Symptome:</strong> Erbrechen, Dehydratation, Lethargie</li>
                        <li><strong>Labor:</strong> Hyponatriämie (<130 mmol/l), Hyperkaliämie (>7 mmol/l)</li>
                        <li><strong>Notfall:</strong> Lebensbedrohlich ohne Behandlung</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Molekulargenetik</h3>
                <div class="pathway-diagram">
                    <h4>CYP21A2-Gen und Pseudogen</h4>
                    
                    <div style="background: #f8fafc; padding: 20px; border-radius: 12px; margin: 20px 0; border: 1px solid #e2e8f0;">
                        <p><strong>Komplexe Genstruktur:</strong></p>
                        <ul>
                            <li><strong>Lokalisation:</strong> Chromosom 6p21.3 (HLA-Komplex)</li>
                            <li><strong>Tandem-Arrangement:</strong> CYP21A2 (aktiv) und CYP21A1P (Pseudogen)</li>
                            <li><strong>TNXA/TNXB:</strong> Benachbarte Gene (Tenascin X)</li>
                            <li><strong>Rekombinations-Hotspot:</strong> Häufige Genmutationen durch unequal crossing over</li>
                        </ul>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Mutationstyp</th>
                            <th>Häufigkeit (%)</th>
                            <th>Enzymaktivität</th>
                            <th>Phänotyp</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Large gene deletion</strong></td>
                            <td>20%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>Komplett fehlend</td>
                        </tr>
                        <tr>
                            <td><strong>I2-Splice (c.293-13A>G)</strong></td>
                            <td>25%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>Häufigste SW-Mutation</td>
                        </tr>
                        <tr>
                            <td><strong>8bp-deletion (c.329_336del)</strong></td>
                            <td>10%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>Frameshift</td>
                        </tr>
                        <tr>
                            <td><strong>I172N (c.515T>A)</strong></td>
                            <td>15%</td>
                            <td>1-2%</td>
                            <td>SV</td>
                            <td>Temperatur-labil</td>
                        </tr>
                        <tr>
                            <td><strong>V281L (c.842G>T)</strong></td>
                            <td>20%</td>
                            <td>20-50%</td>
                            <td>NC</td>
                            <td>Häufigste NC-Mutation</td>
                        </tr>
                        <tr>
                            <td><strong>P30L (c.89C>T)</strong></td>
                            <td>5%</td>
                            <td>30-60%</td>
                            <td>NC</td>
                            <td>Mild</td>
                        </tr>
                    </tbody>
                </table>

                <div class="highlight-box">
                    <h4>Genotyp-Phänotyp Korrelationen</h4>
                    <p><strong>Vorhersagbare Muster:</strong></p>
                    <ul>
                        <li><strong>Null/Null Mutationen:</strong> Immer Salzverlust-Form</li>
                        <li><strong>I172N compound heterozygot:</strong> Meist einfach virilisierend</li>
                        <li><strong>V281L homozygot:</strong> Typisch nicht-klassische Form</li>
                        <li><strong>Severe/Mild Kombinationen:</strong> Intermediäre Phänotypen</li>
                    </ul>
                    
                    <p><strong>Besondere Konstellationen:</strong></p>
                    <ul>
                        <li><strong>TNXA/CYP21A2 Deletionen:</strong> CAH + Ehlers-Danlos Syndrom</li>
                        <li><strong>Chimeric genes:</strong> Variable Expressivität</li>
                        <li><strong>Mosaizismus:</strong> Seltene atypische Verläufe</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Diagnostik</h3>
                <div class="pathway-diagram">
                    <h4>Diagnostischer Algorithmus</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="background: #fef3c7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #f59e0b;">
                            <strong>Verdacht auf CAH</strong><br>
                            Ambige Genitalien / Salzverlustkrise / Hyperandrogenämie
                        </div>
                        <span class="arrow" style="transform: rotate(90deg); color: #f59e0b;">↓</span>
                        
                        <div style="background: #dbeafe; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #3b82f6;">
                            <strong>17-OH-Progesteron (nüchtern, 8 Uhr)</strong><br>
                            Screening-Parameter
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 15px; width: 100%;">
                            <div style="background: #dcfce7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #22c55e;">
                                <strong>>300 ng/ml</strong><br>
                                Klassische CAH sicher
                            </div>
                            <div style="background: #fef3c7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #f59e0b;">
                                <strong>30-300 ng/ml</strong><br>
                                ACTH-Test
                            </div>
                            <div style="background: #fee2e2; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #ef4444;">
                                <strong><30 ng/ml</strong><br>
                                CAH unwahrscheinlich
                            </div>
                        </div>
                        <span class="arrow" style="transform: rotate(90deg); color: #22c55e;">↓</span>
                        
                        <div style="background: #ecfdf5; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #10b981;">
                            <strong>Molekulargenetik + Therapie</strong><br>
                            CYP21A2 Sequenzierung + MLPA
                        </div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>⚡ ACTH-Stimulationstest</h4>
                    <p><strong>Protokoll:</strong></p>
                    <ul>
                        <li><strong>Dosierung:</strong> 250 μg ACTH (Synacthen) i.v./i.m.</li>
                        <li><strong>Zeitpunkte:</strong> 0, 30, 60 Minuten</li>
                        <li><strong>Parameter:</strong> 17-OHP, Kortisol, Androstendion</li>
                        <li><strong>Interpretation:</strong> 60-min 17-OHP >10.000 ng/ml = klassische CAH</li>
                    </ul>
                    
                    <p><strong>Neugeborenenscreening:</strong></p>
                    <ul>
                        <li><strong>Parameter:</strong> 17-OHP aus Trockenblut</li>
                        <li><strong>Timing:</strong> 36-72 Stunden postnatal</li>
                        <li><strong>Cut-off:</strong> Gewichts-adjustiert (Frühgeborene höher)</li>
                        <li><strong>Falsch-positive:</strong> Stress, Frühgeburtlichkeit</li>
                    </ul>
                    
                    <p><strong>Zusätzliche Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Sonographie:</strong> Interne Genitalstrukturen bei ambigen Genitalien</li>
                        <li><strong>Karyotyp:</strong> 46,XX vs. 46,XY Bestätigung</li>
                        <li><strong>Knochelalter:</strong> Advancement bei unbehandelten Patienten</li>
                        <li><strong>MRT NNR:</strong> Hyperplasie beider Nebennieren</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah-andere')">Weiter zu anderen CAH-Formen →</button>
            </div>
        </div>

        <!-- Andere CAH-Formen -->
        <div class="content-section" id="cah-andere">
            <h2 class="section-title">🌟 Andere CAH-Formen</h2>

            <div class="subsection">
                <h3>11β-Hydroxylase-Mangel (CYP11B1)</h3>
                <div class="steroid-pathway">
                    <h4>Pathophysiologie und Klinik</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #f8fafc; padding: 15px; border-radius: 8px; text-align: center; width: 100%;">
                            <h5 style="color: #8b5cf6; margin-bottom: 10px;">5-8% aller CAH-Fälle</h5>
                            <p style="font-size: 0.9em; color: #6b7280;">Zweithäufigste Form der klassischen CAH</p>
                        </div>
                        
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box">11-Deoxykortisol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">↓</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">CYP11B1 (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">11β-Hydroxylase</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">↓</span>
                            <div class="hormone-box decreased">Kortisol ↓↓</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; width: 100%; margin-top: 20px;">
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 8px; border: 2px solid #ef4444;">
                                <h5 style="color: #dc2626; margin-bottom: 10px;">↑ Akkumulation</h5>
                                <div class="hormone-box elevated">11-Deoxykortisol ↑↑</div>
                                <div class="hormone-box elevated">11-Deoxykortikosteron ↑↑</div>
                                <div class="hormone-box elevated">Androgene ↑↑</div>
                            </div>
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 8px; border: 2px solid #22c55e;">
                                <h5 style="color: #16a34a; margin-bottom: 10px;">Klinische Folgen</h5>
                                <p style="color: #16a34a; font-size: 0.9em;">• Hypertonie (DOC!)<br>• Hypokaliämie<br>• Virilisierung<br>• Kein Salzverlust</p>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Parameter</th>
                            <th>21-Hydroxylase CAH</th>
                            <th>11β-Hydroxylase CAH</th>
                            <th>Klinische Bedeutung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Inzidenz</strong></td>
                            <td>1:15.000</td>
                            <td>1:100.000 - 1:200.000</td>
                            <td>21-OHD 10x häufiger</td>
                        </tr>
                        <tr>
                            <td><strong>Hauptmarker</strong></td>
                            <td>17-OH-Progesteron ↑↑</td>
                            <td>11-Deoxykortisol ↑↑</td>
                            <td>Spezifische Biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>Mineralokortikoid</strong></td>
                            <td>Aldosteron ↓ (Salzverlust)</td>
                            <td>DOC ↑ (Hypertonie)</td>
                            <td>Gegensätzliche Effekte</td>
                        </tr>
                        <tr>
                            <td><strong>Virilisierung</strong></td>
                            <td>Ja</td>
                            <td>Ja (oft stärker)</td>
                            <td>Beide betroffen</td>
                        </tr>
                        <tr>
                            <td><strong>Besonderheit</strong></td>
                            <td>Salzverlust möglich</td>
                            <td>Hypertonie charakteristisch</td>
                            <td>Unterscheidungsmerkmal</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>🔍 Diagnostische Besonderheiten</h4>
                    <p><strong>11β-Hydroxylase CAH Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Primärmarker:</strong> 11-Deoxykortisol >20 μg/dl (Normal: <1 μg/dl)</li>
                        <li><strong>ACTH-Test:</strong> 11-Deoxykortisol steigt >50 μg/dl</li>
                        <li><strong>DOC erhöht:</strong> Ursache der Hypertonie und Hypokaliämie</li>
                        <li><strong>17-OHP:</strong> Kann mäßig erhöht sein (DD zu 21-OHD)</li>
                    </ul>
                    
                    <p><strong>Molekulargenetik:</strong></p>
                    <ul>
                        <li><strong>Gen:</strong> CYP11B1 (8q21-22)</li>
                        <li><strong>Häufige Mutationen:</strong> R448H, Q356X, R374W</li>
                        <li><strong>Genotyp-Phänotyp:</strong> Meist gute Korrelation</li>
                        <li><strong>Schwere Formen:</strong> Kompletter Funktionsverlust</li>
                    </ul>
                    
                    <p><strong>Therapie:</strong></p>
                    <ul>
                        <li><strong>Glukokortikoide:</strong> Wie bei 21-OHD</li>
                        <li><strong>Antihypertensiva:</strong> Oft erforderlich (Spironolacton, ACE-Hemmer)</li>
                        <li><strong>Kein Fludrocortison:</strong> Wegen DOC-Exzess kontraindiziert</li>
                        <li><strong>Monitoring:</strong> RR, Kalium, 11-Deoxykortisol</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>17α-Hydroxylase/17,20-Lyase-Mangel (CYP17A1)</h3>
                <div class="pathway-diagram">
                    <h4>Dualer Enzymdefekt</h4>
                    
                    <div style="background: linear-gradient(135deg, #fdf4ff, #fae8ff); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #8b5cf6;">
                        <div style="text-align: center; margin-bottom: 20px;">
                            <h5 style="color: #7c3aed; margin-bottom: 15px;">CYP17A1 - Zwei enzymatische Aktivitäten</h5>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                            <div>
                                <p style="color: #7c3aed; font-weight: 600; margin-bottom: 10px;">17α-Hydroxylase Aktivität:</p>
                                <div style="font-size: 0.9em; color: #7c3aed;">
                                    <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">Pregnenolon → 17-OH-Pregnenolon</div>
                                    <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">Progesteron → 17-OH-Progesteron</div>
                                </div>
                            </div>
                            <div>
                                <p style="color: #7c3aed; font-weight: 600; margin-bottom: 10px;">17,20-Lyase Aktivität:</p>
                                <div style="font-size: 0.9em; color: #7c3aed;">
                                    <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">17-OH-Pregnenolon → DHEA</div>
                                    <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">17-OH-Progesteron → Androstendion</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Hormonsystem</th>
                            <th>Betroffene Hormone</th>
                            <th>Laborwerte</th>
                            <th>Klinische Manifestation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Glukokortikoide</strong></td>
                            <td>Kortisol ↓</td>
                            <td>Kortisol <5 μg/dl</td>
                            <td>Meist asymptomatisch (genug DOC)</td>
                        </tr>
                        <tr>
                            <td><strong>Mineralokortkoide</strong></td>
                            <td>DOC ↑, Aldosteron ↓</td>
                            <td>DOC >5 ng/ml</td>
                            <td>Hypertonie, Hypokaliämie</td>
                        </tr>
                        <tr>
                            <td><strong>Sexualhormone</strong></td>
                            <td>Alle Androgene/Östrogene ↓</td>
                            <td>Testosteron <50 ng/dl</td>
                            <td>Sexuelle Infantilismus</td>
                        </tr>
                        <tr>
                            <td><strong>Biomarker</strong></td>
                            <td>17-OH-Steroide ↓</td>
                            <td>17-OHP <30 ng/ml</td>
                            <td>Diagnostischer Marker</td>
                        </tr>
                    </tbody>
                </table>

                <div class="highlight-box">
                    <h4>Klinisches Spektrum</h4>
                    <p><strong>46,XX Patienten:</strong></p>
                    <ul>
                        <li><strong>Äußere Genitalien:</strong> Normal weiblich (keine Androgenexposition)</li>
                        <li><strong>Pubertät:</strong> Ausbleibende Menarche, fehlende Brustentwicklung</li>
                        <li><strong>Gonaden:</strong> Streak ovaries, keine Östrogen-Produktion</li>
                        <li><strong>Größe:</strong> Oft überdurchschnittlich (fehlende Östrogeneffekte)</li>
                    </ul>
                    
                    <p><strong>46,XY Patienten:</strong></p>
                    <ul>
                        <li><strong>Genitalien:</strong> Weibliches Erscheinungsbild (komplette Androgenresistenz-ähnlich)</li>
                        <li><strong>Interne Strukturen:</strong> Hoden vorhanden, oft intraabdominal</li>
                        <li><strong>Geschlechtsidentität:</strong> Meist weiblich (durch Erziehung)</li>
                        <li><strong>Tumor-Risiko:</strong> Gonadoblastom-Risiko bei Streak gonads</li>
                    </ul>
                    
                    <p><strong>Beide Geschlechter:</strong></p>
                    <ul>
                        <li><strong>Hypertonie:</strong> Durch DOC-Exzess (90% der Patienten)</li>
                        <li><strong>Hypokaliämie:</strong> Oft schwer (<3 mmol/l)</li>
                        <li><strong>Osteoporose:</strong> Durch Hypogonadismus</li>
                        <li><strong>Metabolisches Syndrom:</strong> Durch Kortisolmangel</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>3β-Hydroxysteroid-Dehydrogenase Typ 2 Mangel</h3>
                <div class="case-study">
                    <h4>🧬 Seltene aber schwere CAH-Form</h4>
                    <p><strong>Pathophysiologie:</strong></p>
                    <ul>
                        <li><strong>Enzym:</strong> 3β-HSD2 (HSD3B2-Gen)</li>
                        <li><strong>Funktion:</strong> Δ5-Steroide → Δ4-Steroide</li>
                        <li><strong>Lokalisation:</strong> Nebenniere, Gonaden</li>
                        <li><strong>Inzidenz:</strong> <1:1.000.000</li>
                    </ul>
                    
                    <p><strong>Biochemische Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Δ5-Steroide ↑:</strong> Pregnenolon, 17-OH-Pregnenolon, DHEA</li>
                        <li><strong>Δ4-Steroide ↓:</strong> Progesteron, 17-OHP, Androstendion</li>
                        <li><strong>Ratio-Diagnostik:</strong> Δ5/Δ4-Steroid Ratio >5</li>
                        <li><strong>Schwacher Androgen:</strong> DHEA wenig virilisierend</li>
                    </ul>
                    
                    <p><strong>Klinische Manifestation:</strong></p>
                    <ul>
                        <li><strong>Salzverlust:</strong> Meist schwer (fehlende Mineralokortkoide)</li>
                        <li><strong>Milde Virilisierung:</strong> Weniger als bei 21-OHD</li>
                        <li><strong>46,XY Patienten:</strong> Oft undervirilized, mikropenis</li>
                        <li><strong>Prognose:</strong> Schlecht bei schweren Formen</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>StAR-Protein Defekt (Lipoid CAH)</h3>
                <div class="steroid-pathway">
                    <h4>Schwerstes CAH-Syndrom</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #fee2e2; padding: 20px; border-radius: 10px; width: 100%; border: 2px solid #ef4444;">
                            <div style="text-align: center;">
                                <h5 style="color: #dc2626; margin-bottom: 15px;">StAR = Steroidogenic Acute Regulatory Protein</h5>
                                <p style="color: #dc2626; margin-bottom: 10px;"><strong>Funktion:</strong> Cholesterin-Transport in Mitochondrien</p>
                                <p style="color: #dc2626;"><strong>Bedeutung:</strong> Rate-limiting step der Steroidogenese</p>
                            </div>
                        </div>
                        
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed);">Cholesterin (Cytoplasma)</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #ef4444;">❌</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">StAR-Protein (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">Cholesterin-Transport blockiert</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #ef4444;">❌</span>
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #6b7280, #4b5563);">Cholesterin (Mitochondrien)</div>
                            
                            <div style="margin-top: 20px; text-align: center; background: #fef2f2; padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                                <h5 style="color: #dc2626; margin-bottom: 10px;">Konsequenz: Kompletter Steroidmangel</h5>
                                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); gap: 10px;">
                                    <div class="hormone-box decreased">Kortisol ↓↓</div>
                                    <div class="hormone-box decreased">Aldosteron ↓↓</div>
                                    <div class="hormone-box decreased">Testosteron ↓↓</div>
                                    <div class="hormone-box decreased">Östrogen ↓↓</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="highlight-box">
                    <h4>Klinische Charakteristika</h4>
                    <p><strong>Schwere neonatale Manifestation:</strong></p>
                    <ul>
                        <li><strong>Salzverlustkrise:</strong> Innerhalb weniger Tage, oft letal</li>
                        <li><strong>Adrenale Insuffizienz:</strong> Komplette Steroidproduktion ↓</li>
                        <li><strong>46,XY DSD:</strong> Komplett weibliches Erscheinungsbild</li>
                        <li><strong>Lipid-Akkumulation:</strong> In Nebennieren und Gonaden ("lipoid")</li>
                    </ul>
                    
                    <p><strong>Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Alle Steroide ↓:</strong> Kortisol, Aldosteron, Sexualhormone</li>
                        <li><strong>ACTH-Test:</strong> Kein Anstieg von Steroiden</li>
                        <li><strong>Molekulargenetik:</strong> STAR-Gen Mutationen</li>
                        <li><strong>Bildgebung:</strong> Vergrößerte, "lipoid" Nebennieren</li>
                    </ul>
                    
                    <p><strong>Prognose und Therapie:</strong></p>
                    <ul>
                        <li><strong>Mortalität:</strong> Hoch ohne frühzeitige Diagnose</li>
                        <li><strong>Substitution:</strong> Hydrocortison + Fludrocortison</li>
                        <li><strong>Pubertät:</strong> Sexualhormon-Substitution erforderlich</li>
                        <li><strong>Lebenserwartung:</strong> Normal bei adäquater Therapie</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('steroidogenese')">Weiter zu erweiterten Störungen →</button>
            </div>
        </div>

        <!-- Erweiterte Steroidogenese-Störungen -->
        <div class="content-section" id="steroidogenese">
            <h2 class="section-title">🔬 Erweiterte Steroidogenese-Störungen</h2>

            <div class="subsection">
                <h3>P450-Oxidoreduktase-Defekt (PORD)</h3>
                <div class="pathway-diagram">
                    <h4>Elektron-Transfer-Störung</h4>
                    
                    <div style="background: linear-gradient(135deg, #f0f9ff, #e0f2fe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #0891b2;">
                        <div style="text-align: center; margin-bottom: 20px;">
                            <h5 style="color: #0891b2; margin-bottom: 15px;">P450-Oxidoreduktase (POR) - Universeller Elektronendonor</h5>
                            <p style="color: #0891b2; margin-bottom: 10px;"><strong>Funktion:</strong> NADPH → Cytochrom P450 Enzyme</p>
                            <p style="color: #0891b2;"><strong>Betroffene Enzyme:</strong> CYP17A1, CYP21A2, CYP19A1 (Aromatase)</p>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                            <div>
                                <p style="color: #0891b2; font-weight: 600; margin-bottom: 10px;">Betroffene Pathways:</p>
                                <ul style="font-size: 0.9em; color: #0891b2;">
                                    <li>Kortisol-Synthese ↓ (17α-Hydroxylase)</li>
                                    <li>Androgen-Synthese ↓ (17,20-Lyase)</li>
                                    <li>Östrogen-Synthese ↓ (Aromatase)</li>
                                    <li>Medikamenten-Metabolismus ↓</li>
                                </ul>
                            </div>
                            <div>
                                <p style="color: #0891b2; font-weight: 600; margin-bottom: 10px;">Zusätzliche Merkmale:</p>
                                <ul style="font-size: 0.9em; color: #0891b2;">
                                    <li>Skelettale Malformationen</li>
                                    <li>Antley-Bixler Syndrom</li>
                                    <li>Maternale Virilisierung</li>
                                    <li>Drug metabolism defects</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Schweregrad</th>
                            <th>Enzymaktivität</th>
                            <th>Skelettale Beteiligung</th>
                            <th>Endokrine Störung</th>
                            <th>Prognose</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Schwer</strong></td>
                            <td><5%</td>
                            <td>Antley-Bixler Syndrom</td>
                            <td>Schwere Steroidmangel</td>
                            <td>Oft letal</td>
                        </tr>
                        <tr>
                            <td><strong>Moderat</strong></td>
                            <td>5-20%</td>
                            <td>Milde Dysmorphie</td>
                            <td>Ambige Genitalien</td>
                            <td>Gut mit Therapie</td>
                        </tr>
                        <tr>
                            <td><strong>Mild</strong></td>
                            <td>20-50%</td>
                            <td>Keine/minimal</td>
                            <td>Reproduktive Probleme</td>
                            <td>Normal</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>🏗️ Antley-Bixler Syndrom</h4>
                    <p><strong>Skelettale Malformationen:</strong></p>
                    <ul>
                        <li><strong>Craniosynostose:</strong> Multiple Nähte betroffen</li>
                        <li><strong>Faziale Dysmorphie:</strong> Hypertelorismus, flache Nasenwurzel</li>
                        <li><strong>Extremitäten:</strong> Radiohumeral Synostose, Bowing fractures</li>
                        <li><strong>Wirbelsäule:</strong> Scoliose, vertebrale Malformationen</li>
                    </ul>
                    
                    <p><strong>Endokrine Manifestationen:</strong></p>
                    <ul>
                        <li><strong>46,XY DSD:</strong> Undervirilization bis weibliches Erscheinungsbild</li>
                        <li><strong>Maternale Virilisierung:</strong> Während Schwangerschaft</li>
                        <li><strong>Adrenale Insuffizienz:</strong> Meist mild</li>
                        <li><strong>Pubertätsstörungen:</strong> Verzögert oder ausbleibend</li>
                    </ul>
                    
                    <p><strong>Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Steroid-Profil:</strong> Complex pattern, 17α-hydroxylase + 17,20-lyase deficiency</li>
                        <li><strong>Urin-Steroide:</strong> Pregnanetriol ↑, pregnanetriolone ↑</li>
                        <li><strong>Molekulargenetik:</strong> POR-Gen (7q11.2)</li>
                        <li><strong>Bildgebung:</strong> Skelettale Surveys, 3D-CT Schädel</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Aldosteron-Synthase-Defekt (CYP11B2)</h3>
                <div class="steroid-pathway">
                    <h4>Isolierte Mineralokortikoid-Insuffizienz</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #fef3c7; padding: 15px; border-radius: 8px; text-align: center; width: 100%;">
                            <h5 style="color: #92400e; margin-bottom: 10px;">Corticosterone Methyloxidase Deficiency</h5>
                            <p style="font-size: 0.9em; color: #92400e;">Typ I: CMO-I (11β-Hydroxylase), Typ II: CMO-II (